Michael J. Fox is being recognized by Canada for his Parkinson’s disease activism. The ‘Back to the Future’ actor made a rare ...

The 65-year-old actor and activist was promoted to the rank of companion in the Order of Canada, the highest level within the ...

Bayer's $2.2B U.S. pharma investment is a 2022 plan, not new growth, with most funds allocated to German facilities. - The ...

Doctors noticed Parkinson-like illness after the 1918 flu pandemic. A recent analysis of health records from Finland and the ...

There is still a person behind the diagnosis who wants what every one of us wants — to feel safe, respected, included, ...

Learn about the newest innovation in wearable tech — a smart shoe with an internal AI system that runs on footsteps, not ...

Hyderabad’s CCMB has identified how viral RNA structures may accelerate α-synuclein amyloid formation linked to Parkinson’s ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

AbbVie ( ABBV) announced that the U.S. FDA has approved JUVMO (tavapadon) tablets for the treatment of adults with Parkinson's disease, providing a new oral treatment option for a progressive ...

The FDA approved the dopamine agonist tavapadon (Juvmo) to treat adults with Parkinson's disease, drugmaker AbbVie announced ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.